In Split, Ikaria Looks For Products, While New R&D Play Preps For IPO

In a partial buy-out by new private equity investor Madison Dearborn Partners, Ikaria is refocused on building out its critical care product portfolio, while a new R&D spin-out may take a route to the public markets. Existing investors have already done nicely through a series of dividends.

More from Clinical Trials

More from R&D